SCHEMBL220074

SCHEMBL220074

FC(F)(F)Oc1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
EPHX2 P34913 1/20 0.47
GPR3 P46089 1/20 0.43
CHRNA7 P36544 1/20 0.43
CYP2A6 P11509 1/20 0.42
KIF11 P52732 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.41
WDR5 P61964 1/20 0.41
PDE2A O00408 1/20 0.40
NISCH Q9Y2I1 1/20 0.40
MDM2 Q00987 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
MAOB P27338 1/20 0.39
AOC3 Q16853 1/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7469958 0.97 MAPT (0.45) MAPTEPHX2GPR3CHRNA7CYP2A6
SCHEMBL30056405 0.97 MAPT (0.45) MAPTEPHX2GPR3CHRNA7CYP2A6
Bromide SCHEMBL28835122 0.95 MAPT (0.44) MAPTEPHX2GPR3CHRNA7CYP2A6
Bromide SCHEMBL28835121 0.95 MAPT (0.44) MAPTEPHX2GPR3CHRNA7CYP2A6
SCHEMBL4150750 0.93 KIF11 (0.49) MAPTEPHX2KIF11NISCHALDH1A1
SCHEMBL1393658 0.93 MAPT (0.52) MAPTEPHX2GPR3CHRNA7KIF11
SCHEMBL17281262 0.87 GLB1 (0.47) MAPTEPHX2GPR3CHRNA7PDE2A
SCHEMBL4617903 0.87 KIF11 (0.45) MAPTEPHX2CHRNA7KIF11WDR5
SCHEMBL15207305 0.87 CHRNA7 (0.53) MAPTEPHX2GPR3CHRNA7WDR5
SCHEMBL254957 0.86 MAPT (0.56) MAPTEPHX2GPR3KIF11L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117247383-A Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same 基因技术公司 2023-12-19 CN claimed
CN-112105616-B Pharmaceutical compounds, salts thereof, formulations thereof, and methods of making and using the same 基因技术公司 2023-09-01 CN claimed
CN-116573994-A Direct cross-coupling method of triazine ester and aryl bromide 南京工业大学 2023-08-11 CN claimed
CN-116554009-A Electrophilic cross-coupling reaction method of aryl sulfone or heteroaryl sulfone and aryl bromide 南京工业大学 2023-08-08 CN claimed
EP-3746441-B1 PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME GENENTECH INC (US) 2023-04-05 EP claimed
CN-113801015-B Method for synthesizing aromatic carboxylic acid compound by using carbon dioxide 华南理工大学 2022-11-18 CN claimed
CN-114957312-A Aryl silicon compound of conjugated olefin and preparation method and application thereof 南京工业大学 2022-08-30 CN claimed
CN-114853795-A Arylboron compound of conjugated olefin and preparation method and application thereof 南京工业大学 2022-08-05 CN claimed
CN-113387876-B Nickel-catalyzed direct reduction cross-coupling method for heterocyclic phosphonium salt and aryl bromide and product 南京工业大学 2022-04-15 CN claimed
CN-113801015-A Method for synthesizing aromatic carboxylic acid compound by using carbon dioxide 华南理工大学 2021-12-17 CN claimed
US-20200361933-A1 PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME GENENTECH, INC. 2020-11-19 US claimed
CN-108059606-B Method for preparing metaflumizone intermediate by using urea 扬州工业职业技术学院 2020-03-27 CN claimed
CN-108129358-B Clean and efficient metaflumizone synthesis process 扬州工业职业技术学院 2020-03-24 CN claimed
WO-2019152863-A1 PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME GENENTECH, INC. (US) 2019-08-08 WO claimed
CN-108129358-A A kind of metaflumizone synthesis technology of clean and effective 扬州工业职业技术学院 2018-06-08 CN claimed
CN-108059606-A A kind of method that metaflumizone intermediate is prepared using urea 扬州工业职业技术学院 2018-05-22 CN claimed
CN-104087308-B A kind of trifluoromethoxy end substituted diaryl second alkynes liquid crystal compounds and synthetic method thereof XI'AN INST. OF MODERN CHEMISTRY (CN) 2015-12-09 CN claimed
CN-104087308-A Trifluoromethoxy terminal-substituent diaryl acetylene liquid crystal compounds and synthetic method thereof XIAN MODERN CHEMISTRY RES INST 2014-10-08 CN claimed
US-6462242-B1 BY FORMYLATION OF ARYL BROMIDES TO FORM BENZALDEHYDES AND REDUCTION OF THE LATTER USING A FORMATE BAYER AKTIENGESELLSCHAFT (DE) 2002-10-08 US claimed
EP-1059280-A2 Process for the preparation of benzyl alcohols and their use BAYER AG (DE) 2000-12-13 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361933-A1 PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATIONS THEREOF, AND METHODS OF MAKING AND USING SAME SLC10A1, SLC5A6, SLC26A4 MAPT 862/4885EPHX2 1556/4885GPR3 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.